Table 4.
Demographic and clinical characteristics of COVID-19 infection in people living with HIV included in the reviewed studies (total patients=730)
| Characteristics | N (%) |
|---|---|
| Age (mean±SD/median) | 49.11±9.94/51.5 |
| Sex (n=694) | |
| Male | 551 (79.4) |
| Female | 143 (20.6) |
| Used antiretroviral drugs (n=728) | |
| Yes | 708 (97.2) |
| No | 22 (2.7) |
| CD4 cell count (n=470) | |
| <200/mm3 (ns=20) | 87 (18.5) |
| ≥200/mm3 (ns=20) | 383 (81.5) |
| HIV viral load (n=393) | |
| <50 copies/mL (ns=16) | 352 (89.6) |
| >50 copies/mL (ns=15) | 41 (10.4) |
| Severity (n=728) | |
| Mild-moderate | 596 (81.9) |
| Severe-critical | 132 (18.1) |
| Clinical outcome (n=720) | |
| Death | 68 (9.4) |
| Recovery | 652 (90.6) |
| ART regimen | |
| NRTI | 543 (44.6) |
| NNRTI | 161 (13.2) |
| PI | 119 (9.8) |
| INSTI | 395 (32.4) |
| Comorbidities | |
| Hypertension (ns=16) | 128 (26.3) |
| Body mass index >30 kg/m2 (ns=10) | 72 (14.8) |
| Diabetes mellitus (ns=17) | 61 (12.5) |
| Renal disease/CKD/ESRD (ns=17) | 59 (12.1) |
| Cardiovascular disease (ns=17) | 56 (11.5) |
| Neoplasm (ns=17) | 16 (3.3) |
| Liver disease (ns=17) | 49 (10.1) |
| Respiratory disease (ns=17) | 45 (9.3) |
| Symptoms (n= 453) | |
| Cough (ns=11) | 171 (37.7) |
| Fever (ns=11) | 170 (37.5) |
| Dyspnoea (ns=11) | 112 (24.7) |
COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; N, number of the variable; n, number of reported cases; ns, number of analysed studies; SD, standard deviation; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; CKD, chronic kidney disease; ESRD, end-stage renal disease.